December 17, 2019 / 12:22 PM / 2 months ago

IN BRIEF: In blow to Teva, Fed Circuit won't rehear challenge to weight-loss patent

A federal appeals court on Monday declined to reconsider a patent ruling that blocks Teva Pharmaceutical Industries Limited from selling a generic version of the weight-loss drug Contrave until 2030.

The U.S. Court of Appeals for the Federal Circuit denied Teva’s request for en banc rehearing of an August ruling that upheld a patent owned by Contrave’s manufacturer, Nalpropion Pharmaceuticals, covering the weight-loss drug.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below